Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 28;12(2):190-192.
doi: 10.21037/tlcr-22-906. Epub 2023 Feb 14.

Pleurectomy decortication is the preferred surgical procedure in pleural mesothelioma

Moshe Lapidot  1   2 , Raphael Bueno  1
Affiliations
Editorial

Pleurectomy decortication is the preferred surgical procedure in pleural mesothelioma

Moshe Lapidot et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Pleural mesothelioma (PM); extended pleurectomy decortication (EPD); extra pleural pneumonectomy (EPP); macroscopic complete resection (MCR).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-906/coif). Both authors have no conflicts of interest to declare.

Comment on

References

    1. Janes SM, Alrifai D, Fennell DA. Perspectives on the Treatment of Malignant Pleural Mesothelioma. N Engl J Med 2021;385:1207-18. 10.1056/NEJMra1912719 - DOI - PubMed
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. 10.1200/JCO.2003.11.136 - DOI - PubMed
    1. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. 10.1016/S0140-6736(20)32714-8 - DOI - PubMed
    1. Van Gerwen M, Alpert N, Wolf A, et al. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis 2019;40:529-36. 10.1093/carcin/bgz004 - DOI - PMC - PubMed
    1. Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 2015;196:23-32. 10.1016/j.jss.2015.01.043 - DOI - PMC - PubMed